Novavax Stock Price To Earning
| NVV1 Stock | EUR 8.69 0.29 3.45% |
Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.
Novavax |
Novavax Company Price To Earning Analysis
Novavax's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Novavax has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earning for all Germany stocks is 100.0% higher than that of the company.
Novavax Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.Novavax is currently under evaluation in price to earning category among its peers.
Novavax Fundamentals
| Return On Equity | -8.98 | |||
| Return On Asset | -0.32 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.66) % | |||
| Current Valuation | 484 M | |||
| Shares Outstanding | 85 M | |||
| Shares Owned By Insiders | 0.45 % | |||
| Shares Owned By Institutions | 62.33 % | |||
| Price To Book | 72.32 X | |||
| Price To Sales | 0.45 X | |||
| Revenue | 1.15 B | |||
| Gross Profit | (1.39 B) | |||
| EBITDA | (1.68 B) | |||
| Net Income | (1.74 B) | |||
| Cash And Equivalents | 1.57 B | |||
| Cash Per Share | 20.11 X | |||
| Total Debt | 323.46 M | |||
| Debt To Equity | 8.24 % | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | (7.21) X | |||
| Cash Flow From Operations | 322.95 M | |||
| Earnings Per Share | (15.18) X | |||
| Target Price | 264.2 | |||
| Number Of Employees | 1.54 K | |||
| Beta | 1.72 | |||
| Market Capitalization | 727.55 M | |||
| Total Asset | 2.58 B | |||
| Z Score | 1.2 | |||
| Net Asset | 2.58 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..